Bausch Health Companies Inc. (BHC) Stock Price & Analysis
Bausch Health Companies Inc. (BHC) fell 0.45% to USD 4.43 as of July 25, 2026 at 03:05 UTC, according to Nexqual real-time market data.
BHC last closed at USD 4.45; the session ranged USD 4.41–4.5 on volume of 1,136,687 shares. Market capitalization is $1.65B, with a 52-week range of USD 4.33–8.69 (NYQ). Source: Nexqual, July 25, 2026 at 03:05 UTC.
Key Statistics (as of July 25, 2026 at 03:05 UTC)
| Price | USD 4.43 |
|---|---|
| Change | ▼ 0.45% (down) |
| Previous Close | USD 4.45 |
| Open | USD 4.48 |
| Day Range | USD 4.41 – 4.5 |
| 52-Week Range | USD 4.33 – 8.69 |
| Volume | 1,136,687 shares |
| Market Cap | $1.65B |
| Exchange | NYQ |
Technical Analysis (BHC)
Nexqual's technical model rates BHC "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.47 (neutral) |
| vs SMA50 | Below (USD 5.02) |
| MACD | -0.14 (negative) |
Analyst Ratings (BHC)
Wall Street analysts rate BHC "Hold" based on 5 analysts, with a mean price target of USD 7.3 (range USD 5.5–9), per Nexqual as of July 25, 2026 at 03:05 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 7.3 |
| High Target | USD 9 |
| Low Target | USD 5.5 |
| Buy / Hold / Sell | 0 / 7 / 0 |
Earnings (BHC)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD 1.01 |
| Revenue Estimate | $2.66B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.78 vs est 0.69 ▲ beat |
| 2025-12-31 | USD 1.1 vs est 1.26 ▼ miss |
| 2025-09-30 | USD 1.16 vs est 1.06 ▲ beat |
| 2025-06-30 | USD 0.91 vs est 0.94 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:05 UTC.
Financials & Fundamentals (BHC)
| Total Revenue | $10.53B |
|---|---|
| Revenue Growth (YoY) | +11.70% |
| Gross Margin | +71.04% |
| Operating Margin | +20.64% |
| Profit Margin | -11.47% |
| Current Ratio | 1.32 |
| Total Cash | $1.30B |
| Total Debt | $20.80B |
| Free Cash Flow | $1.12B |
Source: Nexqual, July 25, 2026 at 03:05 UTC.
Financial Health Score (BHC)
Nexqual rates Bausch Health Companies Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 03:05 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 71%, operating 21% |
| Balance Sheet | Mixed — $1.30B cash vs $20.8B debt |
| Cash Flow | Solid — FCF $1.12B, 11% margin |
| Efficiency | Mixed — No data |
Ownership (BHC)
| Insider Ownership | +11.13% |
|---|---|
| Institutional Ownership | +64.84% |
| Shares Outstanding | 373.48M |
| Float | 259.89M |
| Short % of Float | +2.46% |
Source: Nexqual, July 25, 2026 at 03:05 UTC.
Leadership (BHC)
Bausch Health Companies Inc. is led by Thomas J. Appio (age 63), CEO & Director, per Nexqual as of July 25, 2026 at 03:05 UTC.
| CEO & Director | Thomas J. Appio (age 63) |
|---|---|
| Executive VP & CFO | Jean-Jacques Charhon (age 60) |
| President of US Pharma | Aimee J. Lenar (age 49) |
| Executive VP & COO | Mirza Dautbegovic |
| Senior Vice President of Europe & Canada | Cees Heiman |
Major Backers & Investors (BHC)
Notable institutional backers of Bausch Health Companies Inc. include PAULSON & CO. INC., Goldentree Asset Management LP, Royal Bank of Canada, according to Nexqual as of July 25, 2026 at 03:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| PAULSON & CO. INC. | 19.59% |
| Goldentree Asset Management LP | 9.27% |
| Royal Bank of Canada | 3.04% |
| Nomura Holdings Inc. | 2.4% |
| Healthcare of Ontario Pension Plan Trust Fund | 2.14% |
| MFN Partners Management, LP | 1.6% |
| Kohlberg Kravis Roberts & Co. L.P. | 1.4% |
| Goldman Sachs | 1.39% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.9% |
Source: Nexqual, July 25, 2026 at 03:05 UTC.
From Bausch Health Companies Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
- It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
- The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health.
- The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ELAN | Elanco Animal Health Incorporat | USD 24.91 | ▼ 1.7% |
| BLCO | Bausch + Lomb Corporation | USD 16.17 | ▲ 1.38% |
| BHVN | Biohaven Ltd. | USD 14.32 | ▼ 2.92% |
| CPRI | Capri Holdings Limited | USD 15.44 | ▼ 4.46% |
| GDRX | GoodRx Holdings, Inc. | USD 2.96 | ▲ 1.02% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:05 UTC. This page is informational and not investment advice.